'I bleed Biogen': Just months after the big biotech was slammed following the controversial OK of aducanumab, R&D chief Al Sandrock makes an abrupt exit
Two years after Al Sandrock jumped from CMO to the top post in R&D — and just months after the hyper-controversial approval of the experimental Alzheimer’s drug aducanumab (Aduhelm) — Sandrock is planning to step out of his long career at Biogen.
Late Monday evening the big biotech put out word that Sandrock, a longtime fixture in the company after a 23-year stint, is hitting the exit.
Sandrock sent out an elegiac message today as he moved to the sidelines, which was obtained by Endpoints News. Noting he was leaving with his “head held high,” Sandrock noted:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
